Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026

Aspire Biopharma Holdings, Inc.

Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.
Notes mature Feb 19, 2026; convertible at 80% of lowest closing price in prior 5 trading days.
Proceeds to pay off debt and for working capital; RBW Capital Partners received 8% commission.
Registration rights agreement requires resale registration statement filed by Sept 18, 2025.
Company may prepay at 20% premium; conversion capped at 4.99% (or 9.99%) beneficial ownership.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.